Daniel Zagury

This inventor holds 25 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Immunology Research. Top assignees: Neovacs, 21C Bio, Centre National De La Recherche Scientifique. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Zagury. Retrieved from https://idiyas.com/inventor/daniel-zagury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 3)

% Patents Active = 72.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 1.9

ph-index = 7

Forward Citations = 82(Granted Patents)

Company Filing History:

Centre National De La Recherche Scientifique

patents

4. 2 out of 2

Medecine Et Innovation

patents

5. 2 out of 1,853

National Institute of Health and Medical Research

Université Paris Diderot-Paris 7

patents

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

HIV Therapy

Vaccine Development

Regulatory T Cells

Cytokines

Immunogenic Products

Antibodies

Tumor Treatment

Immunomodulators

Antigenic Heterocomplexes

Pharmaceutical Compositions

Inactivated Proteins

Immunosuppressive Agents

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12024558 - Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART (2024-07-02),

2. 11957748 - Vaccine to pathogenic immune activation cells during infections (2024-04-16),

3. 11365392 - Ex vivo generation of MHCII restricted CD4FOXP3regulatory T cells and therapeutic uses thereof (2022-06-21),

4. 11198851 - Ex vivo generation of γδ Foxp3regulatory T cells and therapeutic uses thereof (2021-12-14),

5. 11077185 - Vaccine to pathogenic immune activation cells during infections (2021-08-03),

6. 10632186 - Vaccine to pathogenic immune activation cells during infections (2020-04-28),

7. 8697047 - Stable immunogenic product comprising antigenic heterocomplexes (2014-04-15),

8. 8679483 - High-yield method for the production of human antibodies blocking the biological activity of a human cytokine (2014-03-25),

9. 8372388 - Method for preparing a stable TNF-α vaccine (2013-02-12),

10. 8101165 - Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors (2012-01-24),

11. 7972603 - Stable immunogenic product comprising antigenic heterocomplexes (2011-07-05),

12. 7887811 - Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein (2011-02-15),

13. 7504479 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2009-03-17),

14. 7351554 - Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's (2008-04-01),

15. 7314629 - Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus (2008-01-01),

Title: The Innovative Journey of Daniel Zagury in Medical Patents

Introduction

Daniel Zagury, an esteemed inventor based in Paris, France, has made significant contributions to the field of medical innovation with a remarkable portfolio of 25 patents. His work primarily focuses on the treatment and prevention of infectious diseases, showcasing his dedication to improving healthcare outcomes.

Latest Patents

Among his latest inventions, Zagury has developed a method for inhibiting HIV-1 viral rebound in subjects using interferon inhibitors and antiretroviral therapy (ART). This method involves the administration of a combination of a blocking agent for interferon-alpha (IFN-α), a type III interferon blocking agent, an ART agent, and optionally, an interferon-beta (IFN-β) blocking agent along with a latency-reversing agent.

Additionally, he has pioneered a vaccine aimed at pathogenic immune activation cells during infections. This method seeks to prevent infectious diseases by administering a combination that includes a CD8 vaccine specific for at least one infectious disease-related antigen, an interferon alpha blocking agent, and a stimulant for the production of type III interferon.

Career Highlights

Zagury's career spans notable positions at innovative companies, including Neovacs and 21c Bio. His tenure at these organizations has facilitated his ability to transform groundbreaking ideas into tangible medical solutions, significantly impacting the way infectious diseases are treated.

Collaborations

Throughout his journey, Zagury has collaborated with talented individuals such as Bernard Bizzini and Helene Le Buanec. These partnerships have enriched his research and development efforts, leading to the creation of cutting-edge medical advancements.

Conclusion

Daniel Zagury's contributions to medical innovation exemplify the power of inventive thinking in addressing public health challenges. His 25 patents reflect a commitment to harnessing scientific knowledge for the betterment of society, particularly in the realm of infectious disease prevention and treatment. As his work continues to evolve, the potential for future breakthroughs remains promising.

Profile summary based on public USPTO records.